ArticleApplied biochemistry and biotechnology2026
Span60/Cholesterol Niosomal Formulation as a Transport Vehicle for L-DOPA and Rasagiline Delivery with Potent In Vitro Neuroprotective Effect.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the potential of niosomal drug delivery systems encapsulating L-DOPA and Rasagiline for Parkinson's disease treatment. The aim is to enhance neuroprotective efficacy, reduce cytotoxic and genotoxic effects, and modulate PD-related gene expression. Niosomes were prepared using varying lipid-to-drug and Span 60-to-cholesterol ratios. Characterization included morphology, particle size, polydispersity index, and surface charge using Transmission electron microscopy and Zetasizer. Drug encapsulation efficiency was measured spectrophotometrically, and in vitro release was assessed in PBS (pH 7.4). Compared to free drugs, niosome-encapsulated L-DOPA and Rasagiline exhibited significantly reduced cytotoxicity and enhanced neuroprotective effects. Cytotoxicity of free and encapsulated drugs was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in human dermal fibroblast cells (HDF). SH-SY5Y cells were differentiated into neuron-like cells using all-trans retinoic acid and exposed to methyl-4-phenylpyridinium (MPP+) to induce a PD model. Neuroprotective effects were assessed by comparing drug-loaded niosomes with free drugs. Genotoxicity was evaluated using Hoechst 33258 staining. Real-time quantitative polymerase chain reaction was performed to analyze PINK1 and LRRK2 gene expression. Niosomal formulations showed spherical morphology, nanoscale size, low polydispersity index, negative surface charge, high drug encapsulation, and sustained release. Drug-loaded niosomes exhibited reduced cytotoxicity in HDF cells and greater neuroprotection in MPP+-induced SH-SY5Y cells compared to free drugs, with minimal genotoxicity. PINK1 was upregulated, and LRRK2 was downregulated after treatment with the drug-loaded formulations. L-DOPA and Rasagiline-loaded niosomes demonstrated effective delivery, neuroprotection, and gene modulation with minimal toxicity. These findings demonstrate the potential of niosomal encapsulation of L-DOPA and Rasagiline in an in vitro Parkinson's disease model, and indicate the necessity for further mechanistic and in vivo investigation.
Indexed as
Identifiers
42606779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.